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Abstract
The main objective of this study was to develop a polymeric drug delivery system for paclitaxel, intended to be
intravenously administered, capable of improving the therapeutic index of the drug and devoid of the adverse effects of
Cremophor EL. To achieve this goal paclitaxel (Ptx)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Ptx-
PLGA-Nps) were prepared by the interfacial deposition method. The influence of different experimental parameters on the
incorporation efficiency of paclitaxel in the nanoparticles was evaluated. Our results demonstrate that the incorporation
efficiency of paclitaxel in nanoparticles was mostly affected by the method of preparation of the organic phase and also by
the organic phase /aqueous phase ratio. Our data indicate that the methodology of preparation allowed the formation of
spherical nanometric (,200 nm), homogeneous and negatively charged particles which are suitable for intravenous
administration. The release behaviour of paclitaxel from the developed Nps exhibited a biphasic pattern characterised by an
initial fast release during the first 24 h, followed by a slower and continuous release. The in vitro anti-tumoral activity of
Ptx-PLGA-Nps developed in this work was assessed using a human small cell lung cancer cell line (NCI-H69 SCLC) and
 
compared to the in vitro anti-tumoral activity of the commercial formulation Taxol . The influence of Cremophor EL on

cell viability was also investigated. Exposure of NCI-H69 cells to 25 mg/ml Taxol resulted in a steep decrease in cell
viability. Our results demonstrate that incorporation of Ptx in nanoparticles strongly enhances the cytotoxic effect of the drug

as compared to Taxol , this effect being more relevant for prolonged incubation times.
  2002 Elsevier Science B.V. All rights reserved.
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1 . Introduction activity against a variety of solid tumors, including
breast cancer, advanced ovarian carcinoma, lung
Paclitaxel has been shown to exhibit a significant cancer, head and neck carcinomas, and acute
leukemias [1–4]. However, the success of its clinical
application is mainly limited by its low therapeutic
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travascular (i.v) administration [5]. Presently, the patibility and biodegradation of the polyesters makes

only available formulation for clinical use (Taxol ) them suitable candidates for pharmaceutical purposes
consists of a solution of paclitaxel (6 mg/ml) in a [33]. Recently, some work on the use of PLGA

vehicle composed of Cremophor EL and dehy- nanoparticles as carriers for paclitaxel has been
drated alcohol at a 50:50 (v /v) ratio. This vehicle has published [19,20,23]. Nevertheless, to our knowledge
been associated with severe hypersensitivity re- there are no reports on the literature regarding the
actions and has shown incompatibility with common incorporation of paclitaxel into PLGA nanoparticles
PVC intravenous administration sets [6–10]. In order using the nanoprecipitation method. Besides being
to eliminate the Cremophor based vehicle and in an the simplest method for Nps preparation, involving
attempt to increase the therapeutic efficacy of the only one step for dispersion of the non-toxic organic
drug, alternative dosage forms have been suggested, phase in the aqueous phase, thus avoiding any
including parenteral emulsions [11,12], liposomes purification procedure, it provides high yields of
[13–15], nanoparticles [16–20] and microspheres encapsulation of hydrophobic compounds, and the
[21–24]. formation of particles exhibiting adequate features
Among the new drug delivery systems, polymeric for i.v. administration. The resulting formulations
nanoparticles have been considered as promising were extensively characterized regarding their size,
carriers for anticancer agents. In fact, it has been morphology and charge. In vitro drug release studies
demonstrated that a significant improvement in drug were also performed using the most promising
specificity of action can be reached upon its incorpo- formulation developed in this work. Finally, in vitro
ration into nanoparticles, this effect being mainly anti-tumoral activity of paclitaxel incorporated in the
attributed to changes in tissue distribution and phar- nanoparticles was evaluated using a human small cell
macokinetics [25,26]. These modifications may con- lung cancer cell line (NCI-H69).
sequently result in a reduction in the side-effects and
toxicity of the drug and in an increase in its
therapeutic efficacy. Furthermore, it has been demon- 2 . Materials and methods
strated that nanoparticles can escape from the vas-
culature through the leaky endothelial tissue that 2 .1. Materials
surrounds the tumor and thus accumulate in certain
solid tumors [27,28]. More recently, it was also Paclitaxel was a gift from Bristol Myers Squibb
reported that nanoparticles can overcome the multi- (Portugal). PLGA copolymers (50/50; Resomer RG
drug resistance phenotype mediated by glycoprotein- 502H, MW 6000 and RG 502, MW 14 500) and the
P leading to an increase in drug content inside the 75/25 PLGA copolymer (Resomer RG 755, MW
neoplastic cells [29]. This finding is of great impor- 63 600) were purchased from Boheringer Ingelheim.
tance for the particular case of paclitaxel since Acetone pro analisi was supplied by Merck. Polox-

acquired resistance to the drug has already been amer 188 (Symperonic F68) was obtained from ICI
reported [30]. Other important advantages associated (ICH, France). Dichloromethane (DCM), acetonitrile
with the use of nanoparticles include the ease of their and phosphoric acid (HPLC grade) were purchased
preparation with well-defined biodegradable poly- from Merck. The tetrazolium dye 3-(4,5-di-
mers (ex: PLGA) and their high stability in bio- methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
logical fluids and during storage [31]. (MTT) was obtained from Sigma. Cremophor EL
Hence, the main goal of this work was to develop was kindly provided by BASF (BASF, Portugal).
a polymeric drug delivery system for paclitaxel Water was purified by reverse osmosis (Milli-Q,
 
aiming at avoiding the use of Cremophor EL and Milipore ).
improving the anti-tumoral efficacy of the drug.
For this purpose nanoparticles of PLGA contain- 2 .2. Preparation of paclitaxel-loaded nanoparticles
ing paclitaxel were prepared by the interfacial depo-
sition (nanoprecipitation) method [32]. PLGA was Nanoparticles were prepared by the interfacial
used in this study since the demonstration of biocom- deposition method as previously described by Fessi
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et al. [32]. Briefly, an organic solution of PLGA (100 directly to the polymer (also added as a powder) and
mg) and paclitaxel (0.4 or 1 mg) in acetone (10 ml) this mixture was then solubilized in 10 ml of acetone
was added to an aqueous poloxamer 188 solution (10 (method A); (ii) a solution of paclitaxel in acetone
or 20 ml, 0.25%, w/v) under magnetic stirring at was prepared (final concentration of 0.4 or 1 mg/ml)
room temperature. Following 15 min of magnetic and 1 ml of this solution added to the polymer, being
stirring the acetone was removed under reduced the resulting mixture vortexed vigorously until com-
pressure. To remove the non-incorporated drug, the plete dissolution of the polymer. The volume was
obtained nanosuspension was filtered (S&S ‘Filter completed to 10 ml with acetone immediately before
paper circles’, pore size 1 mm) and ultracentrifuged the addition of the organic phase to the aqueous
twice at 61 7003g for 1 h at 4 8C (Beckman L-80 phase (method B). In addition, the effect of using
ultracentrifuge equipped with a Ti-70 rotor). The copolymers of PLGA with different molecular
supernatant containing the free drug was discarded weights and different organic /aqueous phase ratios
and the pellet was freeze-dried for 24 h (Labconco were also investigated.
Freeze Dry System—Freezone 6 Liter, Kansas City,
MO, USA). 2 .3. Determination of paclitaxel content in the
Drug-free nanoparticles were prepared according nanoparticles
to the same procedure.
In an attempt to investigate the influence of The paclitaxel content in the PLGA nanoparticles
various formulation parameters on drug incorpora- was assayed by HPLC. For this purpose, optimi-
tion efficiency, different experimental conditions zation and validation of a method proposed by Wang
were evaluated (Fig. 1). Two distinct methods for et al. [21] were performed (data not shown). Briefly,
the preparation of the organic phase were tested: (i) a a specific amount of lyophilized nanoparticles was
specific amount of paclitaxel powder was added dissolved in 1 ml DCM and mixed with 5 ml of an
acetonitrile:2 mM phosphoric acid solution (50:50,
v /v). The mixture was then vortexed vigorously for
5 min and DCM was evaporated under a nitrogen
stream until a clear solution was obtained. The final
solution was diluted with acetonitrile:2 mM phos-
phoric acid (50:50, v /v) and used for paclitaxel
analysis.
For HPLC analysis, a reverse-phase Lichrocart
RP 18 column (12533 mm i.d., pore size 5 mm
Merck, KGaA, Purospher ) was used. The column

was protected with a Lichrocart RP 18 pre-column
(434 mm i.d., pore size 5 mm Merck, KGaA,
Purospher ). The column temperature was main-
tained at 40 8C with a column oven. The mobile
phase, a mixture of acetonitrile:2 mM phosphoric
acid (50:50, v /v), was delivered at a flow rate of 1.2
ml /min (Hewlett-Packard 1050 pump series). Sam-
ples were filtered by Acrodisc LC PVDF (13 mm
diameter and 0.45 pore size) and sonicated before
injection. Paclitaxel was quantified by UV detection
(l5227 nm, Hewlett-Packard 1050 series). The area
of each eluted peak was integrated (Integrator Hew-
lett-Packard 1050 series) and used for paclitaxel
quantification. Drug incorporation efficiency (I.E.)Fig. 1. Diagram of the methodology and experimental conditions
used to prepare the different formulations. (%) was expressed as the percentage of the drug in
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the produced nanoparticles with respect to the initial pose, several aliquots (1 ml) of the same nanoparti-
amount (mg) used for the preparation of nanoparti- cle suspension were diluted with phosphate-buffered
cles (Eq. (1)). saline solution (PBS), pH 7.4 (final volume of 20
ml) in a capped conical flask. The flasks were
I.E.(%)5 (amount of drug in Nps /(mg) incubated at 37 8C and shaken horizontally at 160
initial amount of drug )3 100 (1) strokes /min. At preselected time intervals, two flasks(mg)
were withdrawn and nanospheres were separated by
2 .4. Physicochemical characterization ultracentrifugation. After removing the supernatant,
the pellet was washed twice with distilled water and
2 .4.1. Particle size distribution and morphology lyophilized. The amount of residual paclitaxel in the
Particle size distribution (mean diameter and poly- nanoparticles was determined by HPLC using the
dispersity index) was determined by photon correla- same procedure as described above (Section 2.3).
tion spectroscopy (PCS) using a Malvern Autosizer
2c (Malvern Instruments, UK). The analysis was 2 .6. Cells
performed at a scattering angle of 908 at a tempera-
ture of 25 8C using samples appropriately diluted NCI-H69 cells, a human small cell lung cancer
with ultra-purified water. For each sample, the mean (SCLC) cell line, were obtained from America Type
diameter of three determinations was calculated. Culture Collection (ATCC, Manassas, VA, USA).
Values reported are the mean6standard deviation of Cells were cultured in suspension in RPMI-1640
at least three different batches of nanoparticles. medium supplemented with 10% heat-inactivated
The morphology of the nanospheres was ascer- fetal bovine serum (FBS) (Biochrom, Berlin) and
tained by Transmission Electronic Microscopy antibiotics (100 mg/ml of streptomycin and 100
(TEM) (CM-12, Philips, The Netherlands). A drop unit /ml of penicillin, Sigma) at 37 8C in a balanced
of the nanoparticles suspension (10 ml) was placed air humidified incubator with an atmosphere of 5%
on copper electron microscopy grids (Formvar CO . Cells were maintained in an exponential2
filmed) and stained with a 2% (w/v) phosphotungstic growth phase by periodic dilutions with fresh
acid solution (Sigma). After 30 s the sample was medium.
washed with ultra-purified water and the excess fluid
removed with a piece of filter paper. The dried 2 .7. In vitro anti-tumoral activity
sample was then examined.
4Briefly, 8310 viable cells /well were seeded in
2 .4.2. Surface charge 100 ml of growth medium in 96-well microtitre
Nanoparticles were also characterized with respect plates (Costar, Cambridge, MA) [34]. Cells were
to electrophoretic mobility and zeta (z ) potential then incubated with different concentrations of

using a Coulter DELSA 440 (Coulter Corporation, Taxol or paclitaxel-loaded nanoparticles, after
Miami, FL). Samples from the prepared suspensions appropriate dilution of these formulations in 100 ml
were diluted in ultra-purified water and placed in the of culture medium, for 24, 72, 120 or 168 h. In order
measurement cell, with its position adjusted to cover to determine the cytotoxic effect of the vehicle
the previously determined stationary layer. The Cremophor EL and of the polymer used to prepare
electric field applied was 10 V. the nanoparticles, cells were also incubated with
different dilutions of these reagents for the same
2 .5. In vitro release studies periods of time.
The effect of the different treatments on cell
The in vitro release profile of paclitaxel from viability was assessed by the tetrazolium dye assay
PLGA-Nps prepared with the Resomer RG 502 of Mosmann [35]. This assay depends on the cellular
copolymer and containing 1% (w/w) of the drug was reductive capacity to metabolise the yellow tetra-
assessed by determining the residual amount of zolium salt, 3-[4,5-dimethylthiazol-2-yl]-3,5-
paclitaxel present in the nanospheres. For that pur- diphenyltetrazolium bromide dye (MTT), to a highly
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coloured formazan product. Briefly, at the end of the
incubation period with the different formulations,
cells were washed twice with phosphate-buffered
saline solution (PBS, pH adjusted to 7.4) by centrifu-
gation (10 min, 12003g). Cells were then incubated
with 100 ml of a MTT solution (0.5 mg/ml) in
RPMI culture medium without FCS and phenol red
for 4 h at 37 8C. One hundred microlitres of an
isopropanol acidic solution (isopropanol–HCl 0.04
N) were then added in order to dissolve the formazan
crystals formed. The UV absorbance of the solubil-
ized formazan crystals was measured spectrophoto-
metrically (ELISA—Mediators phL, Mediators
Diagnostika,Vienna, Austria) at 570 nm. Cell viabili-
ty was determined by the following equation, in
which Abs and Abs represent thetest cells control cells
amount of formazan determined for cells treated with
the different formulations and for control cells (non-
treated), respectively (Eq. (2)).
Cell viability (%)5 (Abs /Abs )3 100test cells control cells
(2)
3 . Results
3 .1. Incorporation efficiency of paclitaxel in
PLGA-Nps: effect of different experimental
parameters Fig. 2. Incorporation efficiency (%) of paclitaxel in PLGA
nanoparticles. (A) Influence of the method of preparation of
organic phase; (B) influence of copolymer MW and compositionIn an attempt to optimise the amount of paclitaxel
(RG 502H: MW 6000; LA/GA 50:50; RG 502: MW 14 500;incorporated into PLGA nanoparticles, different ex-
LA/GA 50:50; RG 755 MW 63 600; LA/GA 75:25); (C)perimental conditions for the preparation of these Influence of organic /aqueous phase ratio. Ptx-PLGA-Nps wereparticles were evaluated. The influence of the prepa- prepared by the nanoprecipitation method. The free drug was
ration of the organic phase on the incorporation separated by ultracentrifugation and the amount of paclitaxel
incorporated in nanoparticles determined by HPLC as described inefficiency (I.E.) of paclitaxel in PLGA-Nps is illus-
Section 2. Values reported are the mean6standard deviation of attrated in Fig. 2A. As can be observed, using the
least three different batches of nanoparticles.
method A only about 15% of the initial drug loading
is incorporated in the nanoparticles, in contrast to the
100% of incorporation obtained when the organic
phase was prepared by the method B. Therefore, this can be observed, for the two initial drug loadings
latter method was selected to prepare all the other used (0.4 and 1%) the incorporation efficiency of Ptx
formulations. was very high ($90%) and independent of the
Fig. 2B illustrates the influence of the copolymer molecular weight and composition of the copolymers
molecular weight and composition on the I.E. of tested.
paclitaxel. Nps were prepared from PLGA with Finally, the dependence of the I.E. of the drug on
different molecular weight (MW) and with different the organic to aqueous phase ratio was also studied.
lactic acid /glycolic acid (LA/GA) molar ratio. As Data presented in Fig. 2C clearly show that doubling
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the volume of the external aqueous phase, while cles as well as their homogeneous particle size
maintaining constant the volume for the organic distribution.
phase, resulted in a reduction of the incorporation The presence of paclitaxel did not affect the size
efficiency of the drug for all the copolymers tested. of nanoparticles when considering the same copoly-
This reduction was approximately 15% for Resomer mer. However, the characteristics of the copolymer
RG 502H and approximately 20% for Resomer RG used were found to slightly affect the size of both
502 and Resomer RG 755 as compared to the drug-free PLGA-Nps and Ptx-PLGA-Nps, this effect
formulation obtained with 1/1 organic /aqueous being dependent on the copolymer MW.
phase ratio. All formulations exhibited a net negative charge
with z potential values ranging from 233.4 to
223.1 mV. Drug-free Nps prepared with the co-
3 .2. Physicochemical characterization polymers RG 502H and RG 502 showed similar
values for the z potential, while a significant reduc-
Aiming at predicting the in vivo behaviour of the tion in this parameter was observed when the
developed Nps, the physicochemical properties of copolymer RG 755 was used. Regarding the formu-
Ptx-Nps, in terms of their mean diameter, polydis- lations prepared in the presence of paclitaxel, drug
persity index, morphology, electrophoretic mobility incorporation did not affect the z potential of the
and z potential, were evaluated. The effect drug nanoparticles prepared with the copolymers RG
incorporation on such properties was also studied by 502H and RG 755. However, a slight increase was
comparing the results obtained with those for drug- observed for nanoparticles prepared with the polymer
free PLGA-Nps (Table1). The MW and the com- RG 502.
position of the copolymers used to prepare nanoparti-
cles are also presented in order to facilitate the 3 .3. In vitro release studies
interpretation of the obtained results. With respect to
particle size analysis and as illustrated in Table 1, all The in vitro release behaviour of paclitaxel from
systems prepared were nanometric (mean diameter PLGA-Nps prepared with the polymer RG 502 with
,200 nm) and exhibited a narrow size distribution an initial drug loading of 1% (w/w) is shown in Fig.
(polydispersity index ,0.1). The same conclusion 4. As can be observed, the release behaviour of
can be withdrawn from the TEM analysis. Repre- paclitaxel from the polymer matrix exhibited a
sentative TEM microphotographs obtained with the biphasic pattern characterised by a fast initial release
PLGA-Nps (Resomer RG 502) are presented in Fig. during the first 24 h, followed by a slower and
3A,B showing the spherical shape of the nanoparti- continuous release.
Table 1
Physicochemical characteristics of various nanoparticles formulations prepared without (drug-free PLGA-Nps) or with paclitaxel (Ptx-
PLGA-Nps). The Ptx-PLGA-Nps were prepared by the methodology B and the initial drug loading used was 1% (w/w)
Polymer RG 502H RG 502 RG 755
MW: 6000 14 500 63 600
Ratio LA/GA: 50/50 50/50 75/25
Parameters Drug-free Ptx-PLGA Drug-free Ptx-PLGA Drug-free Ptx-PLGA
PLGA-Nps Nps PLGA-Nps Nps PLGA-Nps Nps
MD (nm) 11762 12263 13262 13362 15963 16062
PI 0.0660.02 0.0560.01 0.160.03 0.0960.01 0.0360.02 0.0860.01
EM (mm?cm/V?S) 22.3560.5 22.4860.5 22.660.1 22.060.3 21.8360.3 21.7960.3
z (mV) 230.266.5 231.966.2 233.461.8 225.663.5 223.463.1 223.163.7
After appropriate dilution of the different formulations obtained, mean diameter (MD) and polydispersity index (PI) were measured by
PCS and electrophoretic mobility (EM) and z potential were determined by DELSA as described in Section 2.
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3 .4. In vitro anti-tumoral activity
The cytotoxic activity of paclitaxel, both formu-
 lated in Cremophor EL (Taxol ) (Fig. 5A) and
loaded in PLGA nanoparticles (Fig. 6), was evalu-
ated by assessing cell viability by the MTT assay
using the NCI-H69 cell line. Cells were incubated
with concentrations of paclitaxel ranging from 0.025
to 25 mg/ml. This range of concentrations was
selected because it corresponds to plasma levels of
the drug achievable in humans [36].
As can be seen in Fig. 5A, a marked reduction in
cell viability was observed when NCI-H69 cells were
incubated with 25 mg/ml Taxol for 24 h at 37 8C.
At this concentration, the cell growth was almost
totally inhibited after 72 h of incubation, this effect
Fig. 3. Transmission electronic microphotographs of PLGA (Re-
somer RG 502) nanoparticles. (A) 38800; (B) 388 000.
Fig. 5. Viability of NCI-H69 cells incubated with Taxol (A) or
Fig. 4. Cumulative in vitro release of paclitaxel from PLGA-Nps with the excipient CremophorEL (B). Cells were seeded into
(Resomer RG 502). PLGA-Nps containing paclitaxel 1% (w/w) 96-well plates and incubated with different concentrations of both
were diluted in PBS, incubated at 37 8C and shaken horizontally. formulations for 24, 72, 120 or 168 h at 37 8C as described in
At preselected time intervals, the released drug was separated by Section 2. Following the incubation, cell viability was determined
ultracentrifugation and the residual amount of paclitaxel present in by the MTT assay and expressed as a percentage of control wells
the nanospheres determined by HPLC as described in Section 2. (cells without treatment). Results shown in this figure represent
Each point represents the mean6standard deviation obtained from the mean6standard deviation obtained for at least three indepen-
triplicates of two samples. dent experiments performed in triplicate.
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biological activity [37–39], the possible contribution
of this excipient to the in vitro cytotoxicity observed

when NCI-H69 cells were exposed to Taxol was
also investigated. As can be shown in Fig. 5B, a
significant reduction in cell viability was also ob-
served when cells were exposed to 2.2 mg/ml of this
excipient (added at the same concentration of
Cremophor EL present in a solution of 25 mg/ml
 Taxol ). Similar to what was observed with Taxol
(Fig. 5A), this reduction was more pronounced
following 72 h of incubation, cell growth being
almost totally inhibited following 120 h of incuba-
tion. Still regarding Cremophor EL, it should be
noted that at the lowest concentrations (0.022 and
0.0022 mg/ml) no cytotoxic effect was observed for
the longest incubation times.
Fig. 6A,B illustrates the results obtained when
paclitaxel-loaded nanoparticles were incubated with
the NCI-H69 cells for different times at 37 8C. With
respect to the dependence of cytotoxicity on the type
of the copolymer used, it should be mentioned that
for the Ptx-PLGA-Nps prepared with the copolymer
Fig. 6. Viability of NCI-H69 cells incubated with drug-free Nps RG 502 (Fig. 6A), a reduction of about 30% in cell
or Ptx-PLGA-Nps prepared with the RG 502 copolymer (A) or viability was observed when NCI-H69 cells were
with RG 755 (B). Cells were seeded into 96-well plates and incubated for 24 h with 25 mg/ml of incorporatedincubated with different concentrations of both formulations for
drug. For the same incubation time, no significant24, 72, 120 or 168 h as described in Section 2. Cell viability was
effect was observed for the other concentrationsdetermined by the MTT assay and expressed as a percentage of
control wells (cells without treatment). Results shown in this tested. Although for higher incubation times (72 and
figure represent the mean6standard deviation obtained for at least 120 h), cell viability decreased to 55 and 43%,
three independent experiments performed in triplicate.
respectively, this effect was shown to be independent
of the concentration used. Nevertheless, for the
being maintained for the other incubation times longest incubation time (168 h) a marked cytotoxic
tested. It is interesting to note that no toxicity was effect could be observed for both 2.5 and 25 mg/ml.
observed when cells were incubated with 2.5 mg/ml Under these conditions, Ptx-PLGA-Nps were able to
Taxol for 24 h. However, for lower concentrations mediate similar levels of toxicity to those observed
(0.025 and 0.25 mg/ml Taxol ) a 20% reduction in for 25 mg/ml of the commercially available formula-

cell viability could be seen. For longer incubation tion of paclitaxel (Taxol ).
times no significant differences in cytotoxicity were Paclitaxel loaded-nanoparticles obtained with the
observed among the different concentrations tested RG 755 copolymer, showed a different behaviour
(0.025, 0.25 and 2.5 mg/ml Taxol ). However, as (Fig. 6B). In this case, the incubation time seems to
expected, for each of these concentrations an en- be the most critical parameter for paclitaxel activity.
hancement in cytotoxicity with increasing time of After 24 h of incubation, no cytotoxic effect could be
incubation was observed. Nevertheless, it should be observed for any of the concentrations tested. In-
mentioned that cell growth was never completely creasing times of incubation resulted in an enhance-
inhibited (approximately 30% of viable cells were ment of Ptx-PLGA-Nps cytotoxicity. After 168 h of
determined even after 168 h of exposure). incubation with this formulation, a reduction of
Since it is well recognized that Cremophor EL approximately 63% in cell viability was detected for
(the solvent employed in the Taxol ) has some all concentrations tested.
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In order to determine any possible cytotoxic effect may be that a different interaction between paclitaxel
attributed to the copolymers used to prepare the and the polymer occurs when they are both solubil-
nanoparticles, cell viability was also evaluated upon ized, thus leading to a different incorporation of the
incubation of the cells with different concentrations drug in the nanoparticles. In fact, paclitaxel has a
of drug-free nanoparticles. According to our results complex structure and previous studies have pro-
no cytotoxic effect was observed upon incubation of vided evidence that its conformation in solution, as
these formulations with cells. The results presented well as its molecular interactions, may be dependent
reflect only the effect of the highest copolymer on the type of solvent and on its concentration in the
concentration used (2.5 mg/ml), since similar results organic phase [42,43]. Balasubramanian et al. [43],
were obtained for the other concentrations tested reported differences in paclitaxel conformation and
(data not shown). molecular interactions when its concentration varied
24 23A comparison of the results obtained for both from 10 to 10 M, values that are in the same
formulations (Fig. 6A,B), shows that after 168 h of range as those employing methods A and B, respec-
incubation with either 2.5 or 25 mg/ml of incorpo- tively. Besides, the polymer concentration is also 10
rated drug, Ptx-PLGA-Nps prepared with the RG times higher using method B which may also favours
502 copolymer were able to mediate higher levels of its interaction with the drug.
toxicity than Ptx-PLGA-Nps prepared with the RG The organic /aqueous phase ratio is among the
755. most critical parameters for the spontaneous forma-
tion of colloidal particles by the nanoprecipitation
method [44]. Although the effect of this parameter
4 . Discussion on the particle size distribution has been previously
investigated, there is still a lack of fundamental
Paclitaxel is one of the most promising drugs information on its influence on the incorporation
currently available for cancer therapy. Nevertheless, efficiency of drugs in nanoparticles prepared by this
taking into account the problems associated with the methodology. In this work, an increase in the volume
clinical use of the only available paclitaxel formula- of the external aqueous phase (1 /2 ratio) caused a
tion (Taxol ), it can be deduced that the develop- decrease in the incorporation efficiency of paclitaxel
ment of a suitable carrier system for this drug is in PLGA nanoparticles. Preliminary studies per-
considered to be of prime importance. The main goal formed in our laboratory also revealed that this ratio
of this work was to develop a polymeric delivery led to a significant decrease in the nanoparticles size
system for paclitaxel intended to be intravenously as compared to that obtained when the 1/1 ratio was
administered, capable of increasing the therapeutic used (data not shown). Based on our findings and on
index of the drug and devoid of adverse effects. the results reported in the literature, it is reasonable
The interfacial deposition method (nanoprecipita- to consider that the increase in the specific surface
tion) is recommended for the incorporation of hydro- area caused by the formation of smaller nanodroplets
phobic drugs into polymeric nanoparticles [32,40]. during the emulsification stage of the process, may
Nevertheless, as described by several authors and facilitate the diffusion of the drug to the external
also as demonstrated in this work, the establishment phase along with the solvent, leading to lower
of a protocol that allows Nps precipitation, while incorporation efficiencies [45,46]. It is also possible
avoiding extensive diffusion of the drug along with that the smaller the size of the Nps, the lower the
the solvent aiming at obtaining high values of drug capacity of the polymer matrix to incorporate the
encapsulation is a challenging issue [41]. Taking into drug.
account that both of the organic solutions tested have The physicochemical characteristics of colloidal
the same composition and the same concentration of systems, namely size and surface charge, are recog-
paclitaxel at the moment of their addition into the nized to affect their physical stability and to sig-
aqueous phase, one possible explanation for the nificantly influence their interaction with the bio-
discrepancy of the encapsulation efficiency results logical milieu after in vivo administration, as well as
obtained from the two methods explored in this work the release rate of an incorporated substance and
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their interaction with cells [47,48]. The method used followed by a slower and continuous release of the
in this work allowed the instantaneous and reproduc- drug. Similar patterns have been previously observed
ible formation of Nps exhibiting diameters below for the release of paclitaxel from other PLGA
200 nm and low polydispersity indexes, indicating an polymeric systems [20,56]. The burst release of
homogeneous size distribution. As mentioned above, paclitaxel may be due to the dissolution and diffu-
these findings were confirmed by the TEM data, sion of the drug that was poorly entrapped in the
which also showed that nanospheres were spherical polymer matrix, while the slower and continuous
in shape. Nps were shown to exhibit a negative release may be attributed to the diffusion of the drug
surface charge, which can be attributed to the type of localised in the PLGA core of the nanoparticles. It
polymer used and more specifically to the presence should be noted that the amount of drug released
of polymeric carboxylic groups on the nanoparticle from the Nps developed in this work is within the
surface [49,50]. Nevertheless, the results presented range of the values reported for other PLGA systems
slightly differ from those reported by other authors containing paclitaxel [20,56].
[51–53], which can be attributed to different con- In this study a small cell lung cancer cell line was
ditions of Nps preparation (concentration of the used to determine the anti-tumoral activity of pa-
polymer, concentration and type of drug and con- clitaxel, either incorporated in PLGA-nanoparticles

centration and type of surfactant) and to the com- or in the commercial formulation Taxol . The results
position of the analysis medium used. obtained clearly demonstrated that both the incuba-
With respect to drug-free nanoparticles, a slight tion time and concentration play a major role in the
effect of the copolymer composition on the surface in vitro cytotoxicity of paclitaxel. Cell toxicity was
charge was observed. Nanoparticles prepared with higher for longer periods of incubation with the drug.
RG 502H and RG 502 copolymers (at a 50/50 This finding is consistent with previous reports on
LA/GA ratio) showed similar values of z potential, the in vitro cytotoxicity of paclitaxel against other
while nanoparticles obtained with the RG 755 co- tumour cell lines and is in agreement with the
polymer exhibited a lower z potential. It has been mechanism of action of paclitaxel [36,37]. In fact,
described that the surface charge of nanoparticles for longer incubation periods a larger number of cells
prepared with copolymers may depend on the pro- enter the G2 and M cell cycle phases during which
portion of the different monomers [54]. It is also paclitaxel is more active [57]. This result suggests
accepted that the presence of poloxamer 188, the that a drug delivery protocol that could maintain a
emulsifier used during the preparation of nanoparti- therapeutic concentration of paclitaxel for an extend-
cles, can contribute to a reduction in their surface ed period would be desirable in order to maximize its
charge [54,55]. In fact, it is known that this emul- clinical efficacy.
sifier tends to bind to the nanoparticles surface Although a marked reduction in cell viability was
through hydrophobic interactions involving its poly- observed when NCI-H69 cells were incubated with

oxypropylene chains, while the hydrophilic polyoxy- 25 mg/ml Taxol , cell growth being almost totally
ethylene chains protrude into the surrounding inhibited for longer periods of incubation (72 h),
medium, thus masking the negative surface charges these results should be analysed together with those
present in the nanoparticles. In the light of these observed for the Cremophor EL. In fact, an intrigu-
considerations, it is possible that a stronger inter- ing similarity in the extent of cell toxicity was
action is established between poloxamer 188 and the observed upon incubation of the cells with either
 RG 755 copolymer-based Nps (which has a more Taxol (25 mg/ml) or the excipient Cremophor EL
hydrophobic surface due to the higher proportion of (used at a concentration equivalent to that existing in
LA/GA), as compared to the other copolymer used, a Taxol dose of 25 mg/ml). This result suggests
thus justifying the lower values of z potential that the reduction in cell viability obtained with this
observed. concentration is not only due to paclitaxel activity
The release behaviour of paclitaxel from the but also to the presence of the Cremophor EL.
polymer matrix exhibited a biphasic pattern char- Curiously, when cells were incubated with 2.5 mg/

acterised by a fast initial release during the first 24 h, ml Taxol for 24 h no cytotoxic effect was observed,
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while for the lowest concentrations (0.25 and 0.025

mg/ml Taxol ), a decrease in cell viability was
observed, a fact that can also be related to the
presence of Cremophor EL in the medium. In fact,
it has been reported that, above certain concen-
trations (but below toxic concentrations),
Cremophor EL is able to block cells at the G1
phase of the cell cycle preventing them to enter
G2/M phases and thus hampering the cytotoxic
effect of paclitaxel [37–39].
For the higher concentrations tested, significant
differences in the cytotoxic effect of paclitaxel-
loaded nanoparticles were observed depending on the
copolymer used, the RG 502 causing a larger extent Fig. 7. Viability of NCI-H69 cells incubated with Taxol,
Cremophor EL, drug-free Nps or Ptx-PLGA-Nps. Cells wereof cell death than RG 755. This effect was par-
seeded into 96-well plates and incubated with the differentticularly pronounced for the 24- and 168-h incuba-
formulations for 168 h as described in Section 2. Cell viabilitytion times, which may be attributed to the different
was determined by the MTT assay and expressed as a percentage
characteristics of the copolymers used to prepare the of control wells (cells without treatment). Results shown in this
Nps (i.e., hydrophobic /hydrophilic balance and figure represent the mean6standard deviation obtained for at least
three independent experiments performed in triplicate.MW) that are known to influence the release rate of
a drug from a polymeric system [58,59].
In this work, a correlation can be established cytotoxicity observed is only attributed to the amount
between the cytotoxicity results and the in vitro of paclitaxel released (since empty Nps are non-
release kinetics of the drug from the PLGA-Nps. In toxic). The fact that total inhibition of cell growth
fact, following 24 h of incubation a significant was only observed for the highest concentration
amount of paclitaxel was released and thus available tested suggests that a threshold concentration needs
to mediate some cytotoxicity. This effect increases to be reached in order that paclitaxel can develop
with incubation time most likely due to the drug 100% of cell death.
mechanism of action which requires cell division to The enhancement of paclitaxel activity mediated
occur. by its incorporation into Nps can be explained by the
The advantages of incorporating paclitaxel in the fact that these systems can act as a reservoir for
developed PLGA nanoparticles are illustrated in Fig. paclitaxel, protecting the drug from epimerization
7. Incubation of the cells with 2.5 mg/ml of free and hydrolysis [60,61] and providing not only a
paclitaxel (Taxol formulation) contributed to only sustained release of paclitaxel but also contributing
70% reduction in cell viability, while the same to the maintenance of its activity. In addition, it is
concentration of the drug provided as Ptx-PLGA-Nps reasonable to consider that cells become more prone
allowed a cytotoxic effect of almost 100%. It is to paclitaxel activity when the drug is delivered in
important to mention that for this latter condition the the absence of Cremophor EL (which is the case for
cytotoxic effect was similar to that observed when Nps) since as reported above, this compound can

cells were incubated with 25 mg/ml Taxol , mean- antagonize paclitaxel activity [37–39]. The mecha-
ing that the same cytotoxic effect can be observed nism of drug release from the nanoparticles is also of
with a 10-fold reduction in paclitaxel concentration. crucial importance for the extent of paclitaxel activi-
For the higher concentrations (25 mg/ml), similar ty. In this regard, two distinct but not exclusive
levels of toxicity were observed for Taxol and pathways can justify the enhancement of cytotoxic
Ptx-PLGA-Nps. Nevertheless, it should be empha- activity of anti-tumoral drugs incorporated into Nps:

sized that in the case of Taxol a significant effect is (i) Nps can adsorb onto the cell membrane, leading

attributed to the diluent Cremophor EL (absent in to an increase in drug concentration near the cell
the Nps), whereas in the case of Ptx-PLGA-Nps the surface, thus generating a concentration gradient that
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